Intel stock extends gains after report of possible U.S. government stake
Investing.com - Piper Sandler reduced its price target on Vicarious Surgical Inc. (NYSE:RBOT) to $7.00 from $8.50 while maintaining a Neutral rating following the company’s second-quarter results. According to InvestingPro data, the stock has shown significant momentum with a 16.5% return over the past week, despite three analysts recently revising their earnings expectations downward.
The surgical robotics company reported adjusted earnings per share of -$2.23 for the quarter, exceeding analyst expectations of -$2.50, according to Piper Sandler’s research note.
Vicarious Surgical has removed its goal for first clinical use in humans by year-end, focusing instead on completing a fully integrated, production-equivalent system that would enable design lock and initiate full system verification and validation.
The company plans to implement a 4-6 week assessment of every aspect of its system to verify production readiness before entering clinical trials, a move that Piper Sandler indicates is not due to any fundamental issue with the system but rather to address minor refinements.
The research firm adjusted its 2027 estimates slightly downward, anticipating a delay of several quarters in the company’s clinical timeline.
In other recent news, Vicarious Surgical Inc. reported its Q2 2025 financial performance, emphasizing a notable reduction in operating expenses. The company has strategically shifted its product development timeline to focus on finalizing its robotic surgical system. As part of this strategy, Vicarious Surgical has decided to postpone clinical trials to ensure the system’s readiness. These developments are part of the company’s efforts to enhance cost efficiency. The company’s financial results and strategic decisions reflect a focus on refining its core technology. This approach is intended to position Vicarious Surgical for future growth and operational success. The company’s management has not provided specific timelines for the completion of these initiatives. Investors are closely monitoring these updates as they assess the company’s future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.